EGFR and breast carcinoma: Literature is varied with some clinical trials demonstrating that EGFR targeting agents synergize with cytotoxic chemotherapies [59], [60], while others have failed to show any survival advantage of combination over single-agent therapy in advanced breast cancer patients [58].